Literature DB >> 16375655

Alzheimer's disease and P300: review and evaluation of task and modality.

John Polich1, Jody Corey-Bloom.   

Abstract

Early stage Alzheimer disease patients and matched elderly unaffected controls (n = 16/group) were evaluated with the P300 event-related brain potential (ERP). All subjects performed four oddball tasks that varied systematically in task difficulty and were each presented in the auditory and visual modalities. P300 amplitude was smaller and peak latency longer for the Alzheimer patients compared to elderly control subjects across tasks and modalities. P300 differences between Alzheimer patients and controls were largest for the relatively easy tasks, with little influence of stimulus modality observed. The results suggest that the P300 brain potential is sensitive to Alzheimer's disease processes during its early stages, and that easily performed stimulus discrimination tasks are the clinically most useful. Theoretical and practical implications are reviewed.

Entities:  

Mesh:

Year:  2005        PMID: 16375655     DOI: 10.2174/156720505774932214

Source DB:  PubMed          Journal:  Curr Alzheimer Res        ISSN: 1567-2050            Impact factor:   3.498


  39 in total

1.  Within-subject joint independent component analysis of simultaneous fMRI/ERP in an auditory oddball paradigm.

Authors:  J Mangalathu-Arumana; S A Beardsley; E Liebenthal
Journal:  Neuroimage       Date:  2012-02-22       Impact factor: 6.556

2.  Visual evoked potentials to pattern, motion and cognitive stimuli in Alzheimer's disease.

Authors:  Z Kubová; J Kremlácek; M Valis; J Langrová; J Szanyi; F Vít; M Kuba
Journal:  Doc Ophthalmol       Date:  2010-06-04       Impact factor: 2.379

3.  Using event-related potential P300 as an electrophysiological marker for differential diagnosis and to predict the progression of mild cognitive impairment: a meta-analysis.

Authors:  Shixiang Jiang; Changda Qu; Fengjun Wang; Yupeng Liu; Zhengxue Qiao; Xiaohui Qiu; Xiuxian Yang; Yanjie Yang
Journal:  Neurol Sci       Date:  2015-02-08       Impact factor: 3.307

Review 4.  Updating P300: an integrative theory of P3a and P3b.

Authors:  John Polich
Journal:  Clin Neurophysiol       Date:  2007-06-18       Impact factor: 3.708

5.  A study on cognitive impairment and gray matter volume abnormalities in silent cerebral infarction patients.

Authors:  Wei Luo; Xun Jiang; Xiaofeng Wei; Shanshan Li; Mengxiong Li
Journal:  Neuroradiology       Date:  2015-04-24       Impact factor: 2.804

6.  Objective measurement of visual resolution using the P300 to self-facial images.

Authors:  David J Marhöfer; Michael Bach; Sven P Heinrich
Journal:  Doc Ophthalmol       Date:  2015-05-15       Impact factor: 2.379

Review 7.  At the interface of sensory and motor dysfunctions and Alzheimer's disease.

Authors:  Mark W Albers; Grover C Gilmore; Jeffrey Kaye; Claire Murphy; Arthur Wingfield; David A Bennett; Adam L Boxer; Aron S Buchman; Karen J Cruickshanks; Davangere P Devanand; Charles J Duffy; Christine M Gall; George A Gates; Ann-Charlotte Granholm; Takao Hensch; Roee Holtzer; Bradley T Hyman; Frank R Lin; Ann C McKee; John C Morris; Ronald C Petersen; Lisa C Silbert; Robert G Struble; John Q Trojanowski; Joe Verghese; Donald A Wilson; Shunbin Xu; Li I Zhang
Journal:  Alzheimers Dement       Date:  2014-07-09       Impact factor: 21.566

8.  Faces are more attractive than motion: evidence from two simultaneous oddball paradigms.

Authors:  David J Marhöfer; Michael Bach; Sven P Heinrich
Journal:  Doc Ophthalmol       Date:  2014-03-21       Impact factor: 2.379

9.  Can Functional Magnetic Resonance Imaging Improve Success Rates in CNS Drug Discovery?

Authors:  David Borsook; Richard Hargreaves; Lino Becerra
Journal:  Expert Opin Drug Discov       Date:  2011-06-01       Impact factor: 6.098

Review 10.  Neurophysiological biomarkers for drug development in schizophrenia.

Authors:  Daniel C Javitt; Kevin M Spencer; Gunvant K Thaker; Georg Winterer; Mihály Hajós
Journal:  Nat Rev Drug Discov       Date:  2008-01       Impact factor: 84.694

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.